Synairgen plc - Clarification Regarding COVID-19 Trial
Clarification regarding trial of SNG001 in hospitalised COVID-19 patients
§ The trial of SNG001 in hospitalised COVID-19 patients is a Phase II trial (as clearly stated in the announcements of 18 and 25 March). A Phase II trial is designed to test the efficacy of a drug and takes place before the drug is approved or able to be marketed.
§ The protocol was approved by both MHRA and HRA (as detailed in announcement of 18 March) and further details can be found in respect of the full study on the Company's website https://www.synairgen.com/investors/presentations
§ As per the announcement of yesterday, the Company will be working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible. As with any drug undergoing clinical trials,
The Company will provide additional updates in due course and will continue with further analysis of the data from the trial.
For further enquiries, please contact:
Tel: + 44 (0) 23 8051 2800
Tel: + 44 (0) 20 7220 0500
Tel: +44 (0) 20 3709 5700
Notes for Editors
The COVID-19 study
COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people and those with co-morbidities such as heart and lung complications or diabetes are at greatest risk of developing severe or fatal disease.
Interferon beta (IFN-beta) potential applicability to COVID-19
Interferon beta is a naturally occurring protein, which orchestrates the body's antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in 'at-risk' patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2 and MERS-CoV, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells either prevents or greatly diminishes cell damage and viral replication, respectively.
Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung, along with improving lung function in patients with a respiratory viral infection.
This information is provided by RNS, the news service of the
Quick facts: Synairgen PLC
Market Cap: £239.09 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE